NCT00834704View on ClinicalTrials.gov

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

November 30, 2012

Conditions
Solid Tumor
Interventions
DRUG

PEGPH20

PEGylated recombinant human hyaluronidase

Trial Locations (3)

37203

Sarah Cannon Research Institute, Nashville

85258

T Gen Clinical Research Services, Scottsdale

90404

Premiere Oncology, Santa Monica

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY